AC 3056

Drug Profile

AC 3056

Latest Information Update: 06 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Amylin Pharmaceuticals; sanofi-aventis
  • Class
  • Mechanism of Action Antioxidants; Cholesterol inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis; Coronary artery restenosis; Vascular restenosis

Most Recent Events

  • 30 Jun 2005 Discontinued - Phase-I for Atherosclerosis in USA (PO)
  • 30 Jun 2005 Discontinued - Phase-I for Coronary artery restenosis in USA (PO)
  • 30 Jun 2005 Discontinued - Phase-I for Vascular restenosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top